Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, Burton L, Cappelli LC, Castells M, Cohen J, Dewan AK, Fadden R, Guggina L, Hegde A, Huang V, Johnson DB, Kaffenberger B, Kroshinsky D, Kwatra S, Kwong B, Lacouture ME, Larocca C, Leventhal J, Markova A, McDunn J, Mooradian MJ, Naidoo J, Choi J, Nambudiri V, Nelson CA, Patel AB, Pimkina J, Rine J, Rubin KM, Sauder M, Shaigany S, Shariff A, Sullivan RJ, Zubiri L, Reynolds KL, LeBoeuf NR. Chen ST, et al. Among authors: zubiri l. J Immunother Cancer. 2024 Apr 10;12(4):e007675. doi: 10.1136/jitc-2023-007675. J Immunother Cancer. 2024. PMID: 38599660 Free PMC article.
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD, Mooradian MJ, Sheehan DF, Zubiri L, Lumish MA, Gainor JF, Reynolds KL, Kong CY. Criss SD, et al. Among authors: zubiri l. JAMA Oncol. 2019 Mar 1;5(3):358-365. doi: 10.1001/jamaoncol.2018.5449. JAMA Oncol. 2019. PMID: 30543349 Free PMC article.
Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors.
Leaf RK, Ferreri C, Rangachari D, Mier J, Witteles W, Ansstas G, Anagnostou T, Zubiri L, Piotrowska Z, Oo TH, Iberri D, Yarchoan M, Salama AKS, Johnson DB, Leavitt AD, Rahma OE, Reynolds KL, Leaf DE. Leaf RK, et al. Among authors: zubiri l. Am J Hematol. 2019 May;94(5):563-574. doi: 10.1002/ajh.25448. Epub 2019 Mar 13. Am J Hematol. 2019. PMID: 30790338 Free PMC article. Clinical Trial.
Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study.
Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, Reynolds KL, Dougan M, Chen ST. Molina GE, et al. Among authors: zubiri l. J Am Acad Dermatol. 2020 Mar;82(3):743-746. doi: 10.1016/j.jaad.2019.07.049. Epub 2019 Jul 23. J Am Acad Dermatol. 2020. PMID: 31349048 Free PMC article. No abstract available.
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, Cortazar FB, Leaf DE, Mooradian MJ, Villani AC, Sullivan RJ, Reynolds K, Sise ME. Seethapathy H, et al. Among authors: zubiri l. Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1692-1700. doi: 10.2215/CJN.00990119. Epub 2019 Oct 31. Clin J Am Soc Nephrol. 2019. PMID: 31672794 Free PMC article.
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy.
Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR, Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M, Reynolds KL. Zubiri L, et al. Oncologist. 2020 Mar;25(3):e398-e404. doi: 10.1634/theoncologist.2018-0883. Epub 2019 Nov 21. Oncologist. 2020. PMID: 32162817 Free PMC article.
85 results